Does squamous cell carcinoma responde to tarceva?
wasenf, I quote here, from the OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting, which stated that 鈥淭arceva is currently approved as a monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior…